Efficacy of vaccination of cattle with the Leptospira interrogans serovar hardjo type hardjoprajitno component of a pentavalent Leptospira bacterin against experimental challenge with Leptospira borgpetersenii serovar hardjo type hardjo-bovis

Carol L. Rinehart Boehringer Ingelheim Vetmedica Incorporated, 2621 N Belt Hwy, St Joseph, MO 64506.

Search for other papers by Carol L. Rinehart in
Current site
Google Scholar
PubMed
Close
 PhD
,
Alicia D. Zimmerman Rural Technologies Incorporated, 1008 32nd Ave, Brookings, SD 57006.

Search for other papers by Alicia D. Zimmerman in
Current site
Google Scholar
PubMed
Close
 DVM
,
Robin E. Buterbaugh Rural Technologies Incorporated, 1008 32nd Ave, Brookings, SD 57006.

Search for other papers by Robin E. Buterbaugh in
Current site
Google Scholar
PubMed
Close
 MS
,
Rika A. Jolie Boehringer Ingelheim Vetmedica Incorporated, 2621 N Belt Hwy, St Joseph, MO 64506.

Search for other papers by Rika A. Jolie in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, MBA
, and
Christopher C. L. Chase Rural Technologies Incorporated, 1008 32nd Ave, Brookings, SD 57006.
Department of Veterinary and Biomedical Science, College of Agriculture and Biological Sciences, South Dakota State University, Brookings, SD 57007.

Search for other papers by Christopher C. L. Chase in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To evaluate the efficacy of vaccination with the Leptospira interrogans serovar hardjo type hardjoprajitno component of a pentavalent Leptospira bacterin against a virulent experimental challenge with Leptospira borgpetersenii serovar hardjo type hardjo-bovis strain 203 in cattle.

Animals—Fifty-five 6-month-old Holstein heifers.

Procedures—Heifers that were negative for persistent infection with bovine viral diarrhea virus determined via immunohistochemical testing and negative for Leptospira interrogans serovar pomona, Leptospira interrogans serovar hardjo, Leptospira interrogans serovar grippotyphosa, Leptospira interrogans serovar bratislava, Leptospira interrogans serovar canicola, and Leptospira interrogans serovar icterohaemorrhagiae determined via microscopic agglutination assay were enrolled in the study. Two heifers were separated and used for the challenge passage. The remaining heifers were vaccinated twice with a commercial pentavalent bacterin or a sham vaccine 21 days apart and subsequently challenged with L borgpetersenii serovar hardjo type hardjo-bovis strain 203. Urinary shedding, antibody titers, and clinical signs of leptospirosis infection were recorded for 8 weeks after challenge.

Results—Heifers that received the pentavalent bacterin did not shed the organism in urine after challenge and did not have renal colonization at necropsy. Heifers that were sham vaccinated shed the organism in urine and had renal colonization.

Conclusions and Clinical Relevance—Results provided evidence that a pentavalent Leptospira vaccine containing L interrogans serovar hardjo type hardjoprajitno can provide protection against challenge with L borgpetersenii serovar hardjo type hardjo-bovis strain 203. It is important to demonstrate cross-protection that is vaccine specific against disease-causing strains of organisms that are prevalent under field conditions.

Abstract

Objective—To evaluate the efficacy of vaccination with the Leptospira interrogans serovar hardjo type hardjoprajitno component of a pentavalent Leptospira bacterin against a virulent experimental challenge with Leptospira borgpetersenii serovar hardjo type hardjo-bovis strain 203 in cattle.

Animals—Fifty-five 6-month-old Holstein heifers.

Procedures—Heifers that were negative for persistent infection with bovine viral diarrhea virus determined via immunohistochemical testing and negative for Leptospira interrogans serovar pomona, Leptospira interrogans serovar hardjo, Leptospira interrogans serovar grippotyphosa, Leptospira interrogans serovar bratislava, Leptospira interrogans serovar canicola, and Leptospira interrogans serovar icterohaemorrhagiae determined via microscopic agglutination assay were enrolled in the study. Two heifers were separated and used for the challenge passage. The remaining heifers were vaccinated twice with a commercial pentavalent bacterin or a sham vaccine 21 days apart and subsequently challenged with L borgpetersenii serovar hardjo type hardjo-bovis strain 203. Urinary shedding, antibody titers, and clinical signs of leptospirosis infection were recorded for 8 weeks after challenge.

Results—Heifers that received the pentavalent bacterin did not shed the organism in urine after challenge and did not have renal colonization at necropsy. Heifers that were sham vaccinated shed the organism in urine and had renal colonization.

Conclusions and Clinical Relevance—Results provided evidence that a pentavalent Leptospira vaccine containing L interrogans serovar hardjo type hardjoprajitno can provide protection against challenge with L borgpetersenii serovar hardjo type hardjo-bovis strain 203. It is important to demonstrate cross-protection that is vaccine specific against disease-causing strains of organisms that are prevalent under field conditions.

All Time Past Year Past 30 Days
Abstract Views 251 0 0
Full Text Views 1092 534 34
PDF Downloads 607 257 9
Advertisement